Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

16.37
-0.2700-1.62%
Post-market: 16.370.00000.00%16:22 EDT
Volume:611.10K
Turnover:10.00M
Market Cap:2.14B
PE:13.78
High:16.56
Open:16.30
Low:16.13
Close:16.64
Loading ...

February 2025's Top Stocks That May Be Trading Below Estimated Value

Simply Wall St.
·
19 Feb

3 Stocks That Might Be Trading Below Their Estimated Value

Simply Wall St.
·
19 Feb

US Stocks That Might Be Trading At A Discount In February 2025

Simply Wall St.
·
18 Feb

February 2025's Leading Stocks Trading Below Estimated Fair Value

Simply Wall St.
·
18 Feb

February 2025's Estimated Value Stocks For Savvy Investors

Simply Wall St.
·
18 Feb

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Business Wire
·
18 Feb

3 US Stocks That May Be Up To 33.6% Below Intrinsic Value Estimates

Simply Wall St.
·
18 Feb

3 Stocks Estimated To Be Undervalued By Up To 39.8%

Simply Wall St.
·
18 Feb

Three Companies Trading Below Estimated Value For Savvy Investors

Simply Wall St.
·
18 Feb

'Gamechanger': Top broker says this ASX mining share can rise over 100%

MotleyFool
·
18 Feb

Discover 3 US Stocks Estimated To Be Trading At Discounts Of Up To 41.5%

Simply Wall St.
·
17 Feb

3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 38.7%

Simply Wall St.
·
17 Feb

3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value

Simply Wall St.
·
17 Feb

3 Stocks Estimated To Be Undervalued By Up To 40.9% Offering Potential Value

Simply Wall St.
·
17 Feb

3 Stocks Estimated To Be Trading At Discounts Of Up To 23.3%

Simply Wall St.
·
17 Feb

February 2025's Noteworthy Stocks Possibly Priced Below Estimated Fair Value

Simply Wall St.
·
17 Feb

Lunch Wrap: ASX dips after record high; banks take hit on thinning margins

Stockheads
·
17 Feb

Why is this ASX mining stock surging 30% on Monday?

MotleyFool
·
17 Feb

Chalice makes metallurgical breakthrough with Gonneville PFS

The Market Herald
·
17 Feb

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Business Wire
·
16 Feb